TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03090685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: True auriculotherapy with seeds
Description: Roasted edible mustard seeds with \~ 2mm diameter fixed with adhesive tape in 4 to 5 specific body points to control musculoskeletal pain.
Study: NCT03090685

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Auriculotherapy with seeds
Description: Roasted edible mustard seeds with \~ 2mm diameter fixed with adhesive tape at 4 points located in the auricular lobe not specific for musculoskeletal pain.
Study: NCT01380808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine and pseudomonas aeruginosa combination
Description: capecitabine 1000mg/m2 bid, po. pseudomonas aeruginosa 0.5ml loading dose,1ml qod ih.
Study: NCT02817672

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRIME 1.0
Description: Mobile application designed to improve psychosocial functioning and motivational deficits (sans NLP-powered dashboard).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIME 2.0
Description: Mobile application designed to improve psychosocial functioning and motivational deficits (with NLP-powered dashboard).
Study: NCT03308864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Adolescents
Description: Experimental: Interpersonal Psychotherapy for Adolescents (IPT-A) IPT-A is a manualized intervention for depression that targets adolescents' interpersonal context and social supports as mechanisms of change. It will be provided in accordance with the treatment manual by Child and Adolescent Outpatient Service clinicians over the course of 12-16 50-minute sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual will consist of the standard care for adolescent depressive symptoms at CAOS. TAU is not manualized; it is consistent with care typically provided in community settings. Therapists establish a working alliance, are empathetic, reflect expressed affect, and discuss options for coping with concerns as initiated by the adolescent.
Study: NCT03301181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3111 (Arm A)
Description: 320 mg BGB-3111 single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg rifampin once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3111 (Arm B)
Description: Up to 80 mg BGB-3111 single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg itraconazole once daily
Study: NCT04267211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Illustrated handout at prenatal consult
Description: Illustrated consult group will be given an illustration paper describing the majority of the issues discussed at the prenatal consult

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Prenatal Consult
Description: Standard prenatal consult
Study: NCT01463813

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 40 micrograms (1600 IU) per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 80 micrograms (3200 IU) per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo
Study: NCT04617366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized rTMS strategy
Description: It will adjust the rTMS parameters based on the results of fNIRS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rTMS strategy
Description: The patients will always be given low-frequency rTMS to contralesional M1.
Study: NCT03071783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum extraction intelligent system
Description: Vacuum extraction intelligent system - this is the intervention
Study: NCT02629159

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Adalimumab
Description: Administered by subcutaneous injection once every other week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Adalimumab
Description: Administered by subcutaneous injection once every other week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered by subcutaneous injection once every other week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Administered by subcutaneous injection once every other week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Upadacitinib
Description: Tablets taken orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Upadacitinib
Description: Tablets taken orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Upadacitinib
Description: Tablets taken orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablets taken orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets taken orally once a day
Study: NCT03433222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HF-LED-RL Phototherapy
Description: The starting dose of 480 J/cm2 will be administered to Group 1's HF-LED-RL phototherapy randomized subjects and the HF-LED-RL dose will be escalated in the subsequent group to 640 J/cm2. Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity in 2 or more subjects and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mock Therapy
Description: Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit. The mock therapy unit only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks.
Study: NCT03132181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Patient will be treaded according to standard care but additionally take one tablet Empagliflozin per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will be treaded according to standard care but additionally take one tablet placebo per day
Study: NCT00956254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray
Description: Fentanyl was supplied in single-dose glass vials assembled into a delivery device to be used as a sublingual spray.
Study: NCT04687501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality in gynaecological surgery in the pre- and postoperative setting
Study: NCT05365763

Intervention type: BEHAVIORAL
Intervention: Simulated telehealth serious illness conversation visit
Description: The study team will instruct the participant to relax, and record biometric data for a total 7 minutes (the beginning two minutes is to allow for physiologic adaptation).~Simulated Encounter The study team will train experienced actors in the same case, a patient with a metastatic soft tissue sarcoma already on second-line chemotherapy. The physicians will receive a simulated medical file that contains a prognosis in a single format: a range-based, time prognosis (e.g. months to a year). The actor script and medical file will be developed by a multidisciplinary team (e.g. oncologist, palliative care, emotion scientist). The encounter will occur via tele-video platform (ZOOM®) and will be video-recorded. During the encounter participant physicians will wear three biometric sensors.

Intervention type: BEHAVIORAL
Intervention: Simulated telehealth serious illness conversation visit
Description: The study team will instruct the participant to relax, and record biometric data for a total 7 minutes (the beginning two minutes is to allow for physiologic adaptation).~Simulated Encounter The study team will train experienced actors in the same case, a patient with a metastatic soft tissue sarcoma already on second-line chemotherapy. The physicians will receive a simulated medical file that contains a prognosis in a single format: a range-based, time prognosis (e.g. months to a year). The actor script and medical file will be developed by a multidisciplinary team (e.g. oncologist, palliative care, emotion scientist). The encounter will occur via tele-video platform (ZOOM®) and will be video-recorded. During the encounter participant physicians will wear three biometric sensors.
Study: NCT00361595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 5 mg zoledronic acid administered in a single 15 minute IV
Study: NCT00573001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/Emtricitabine (Truvada) and Nevirapine
Description: Tenofovir/Emtricitabine(Truvada) 245/200mg 1cp/day ; Nevirapine 200mg 2cp/day after first 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine/Efavirenz (Atripla)
Description: Tenofovir/Emtricitabine/Efavirenz (Atripla) 300/200/600mg 1cp/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)
Description: Tenofovir (Viread) 300mg 1cp/day ; Lopinavir/Ritonavir (Aluvia) 400/100mg 4cp/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/Emtricitabine (Truvada) and Zidovudine
Description: Tenofovir/Emtricitabine (Truvada) 245/200mg 1cp/day ; Zidovudine 300mg 2cp/day
Study: NCT04284865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web Platform
Description: The intervention involves the use of the web platform for 12 months combined with a monthly phone follow-up.
Study: NCT04670536

Intervention type: DEVICE
Intervention: PASS LP implants
Description: Thoraco lumbar arthrodesis

Intervention type: DEVICE
Intervention: PASS DEGEN
Description: Thoraco lumbar arthrodesis

Intervention type: DEVICE
Intervention: PASS TULIP PRIME
Description: Thoraco lumbar arthrodesis
Study: NCT02899143

Intervention type: DRUG
Group type: OTHER
Intervention: Antibiotic
Description: Targeted antimicrobial therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Targeted antimicrobial therapy
Study: NCT01920360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SULPHUROUS WATERS IMMERSION BATHS
Description: SULPHUROUS WATERS IMMERSION BATHS: The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NOT SULPHUROUS WATERS IMMERSION BATHS
Description: NOT SULPHUROUS WATERS IMMERSION BATHS:The baths will be held in individual tubs, properly disinfected, supplied with not sulphur thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONTROL GROUP
Description: CONTROL GROUP: This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
Study: NCT02638701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Please see protocol for details.
Study: NCT01760161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic potassium chloride
Description: Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
Study: NCT03885271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hall Technique
Description: The Hall technique is a simplified method of utilizing stainless steel crowns in treatment of carious primary molars. The SSC is cemented onto the carious tooth using glass ionomer cement. Since there is no need for carious lesion removal, the use of local anesthesia is not mandate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formecresol Pulpotomy
Description: Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
Study: NCT03899454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Garcinia-mangostana-L-rind and Solanum-Lycopersicum-Fructus mixture-extract
Description: Administration of mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo Control
Study: NCT04172051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tony Robbins Date with Destiny
Description: DWD is a 6-day immersive transformational experience led by Tony Robbins. It will be held at the PALM BEACH, FLORIDA Convention Center from December 5th through December 10th. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tony Robbins Date with Destiny
Description: DWD is a 6-day immersive transformational experience led by Tony Robbins. It will be held at the PALM BEACH, FLORIDA Convention Center from December 5th through December 10th. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
Study: NCT01739751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pedometers
Description: portable device that estimate the number of steps walked daily
Study: NCT02049047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be orally administered at the dosage of 10 mg once daily. Each cycle will be considered as 21 days of treatment. Tumor assessment will be done every two cycles.Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.
Study: NCT01512264

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim SuperRapid
Description: This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim SuperRapid
Description: This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Magstim SuperRapid
Description: This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim SuperRapid
Description: This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
Study: NCT01194440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV
Study: NCT00065429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-10901
Description: I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-10901
Description: I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-10901
Description: I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease.
Study: NCT04058327

Intervention type: DIAGNOSTIC_TEST
Intervention: neurophysiological tests, blood biomarkers.
Description: Let the patients do neuropsychological tests and detect blood biomarkers.
Study: NCT00065429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-10901
Description: I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-10901
Description: I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease.
Study: NCT05501093

Intervention type: OTHER
Intervention: sample collection
Description: Blood, plaque, and other oral samples

Intervention type: OTHER
Intervention: sample collection
Description: Blood, plaque, and other oral samples
Study: NCT00854828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical intervention
Description: Surgical intervention as appropriate for adults with symptomatic lumbar scoliosis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative intervention
Description: Non operative intervention as appropriate for treatment of adults with symptomatic lumbar scoliosis such as: injections, medications, physical therapy, etc.
Study: NCT03260569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Nitric Oxide
Description: Patients randomized to this arm will receive inhaled nitric oxide 20 parts per million.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nitrogen plus oxygen
Study: NCT01704079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTAP101 30 μg capsules
Description: CTAP101 30 μg capsule taken daily at bedtime

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pill to CTAP101 30 μg capsules
Description: Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill to CTAP101 30 μg capsules
Description: Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
Study: NCT01314118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate in combination with prednisone
Description: Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
Study: NCT02181166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy
Study: NCT04583722

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: AX-olive oil-PP emulsion
Description: single dose and plasma samples

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AX-olive oil-PP emulsion
Description: single dose and plasma samples
Study: NCT02992197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix, dose 1
Description: Rotarix, dose 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix, dose 1
Description: Rotarix, dose 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix, dose 2
Description: Rotarix, dose 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Rotarix dose 2)
Description: Sterile water to provide volume equivalent as a second dose of Rotarix
Study: NCT02181166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isquemic compression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High voltage electrical stimulation
Study: NCT04133961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine infusion 0.3ml/kg/hour (equivalent to 0.5mcg/kg/min, phenylephrine dilution is 100mcg/ml in 20ml syringe)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline infusion 0.3ml/kg/hour (normal saline in 20ml syringe)
Study: NCT02426177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: anti-hypertensive agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: calcium channel blocker ,for lowering blood pressure
Study: NCT01213212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: Caloric restriction.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: Diet ad libitum
Study: NCT03742037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod 0.5 mg
Description: Cenerimod will be supplied as a film-coated tablets at the dose of 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod 1 mg
Description: Cenerimod will be supplied as a film-coated tablets at the dose of 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod 2 mg
Description: Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod 4 mg
Description: Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cenerimod 2 mg (ex-4 mg)
Description: Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
Study: NCT04001868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suboccipital inhibition
Description: With the patient in the supine position and the therapist sitting at the head of the bed with the elbows resting on its surface. The therapist palpates the cervical spinous processes and slides the fingers upwards until contacting the posterior projection of the posterior arch of the atlas. Then, flexing the metacarpophalangeal at 90 degrees slowly raises the skull. The therapist's hands should remain together and the base of the skull should rest on his palms pressing with the index, middle and ring fingers of each hand in a sustained manner, but without causing pain. This pressure must be maintained during 4 minutes.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo technique
Description: A superficial contact in the same area as the intervention, to rule out the exteroceptive effect associated with the therapist's contact.